Enasidenib (Compound)

Synonyms:Enasidenib, 1446502-11-9, AG-221, IDHIFA, AG-221 (Enasidenib), Enasidenib [INN], CC-90007 Free Base, AG 221, 2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol, AG-221(Enasidenib), 3T1SS4E7AG, 2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol, 2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol, 2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol, 2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, 2-Propanol, 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]-, 2-methyl-1-({4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl}amino)propan-2-ol, UNII-3T1SS4E7AG, enasidenibum, AG221, AG-221; Enasidenib, Enasidenib; AG-221, ENASIDENIB [MI], Enasidenib (USAN/INN), Enasidenib [USAN:INN], ENASIDENIB [USAN], ENASIDENIB [WHO-DD], GTPL8960, CHEMBL3989908, SCHEMBL15102202, EX-A654, CHEBI:145374, DTXSID801027942, HMS3873D03, AMY38698, BCP16041, BDBM50503251, MFCD29472245, NSC788120, s8205, AKOS026750439, CCG-269476, CS-5017, DB13874, NSC-788120, SB19193, NCGC00479249-03, NCGC00479249-05, AC-31318, AS-75164, HY-18690, FT-0700204, D10901, A857662, EN300-21679954, J-690181, Q27077182, B0084-470859, AG-221; AG 221; AG221; CC-90007; CC 90007; CC90007, 1802003-09-3, 69Q

Pubchem:PUBCHEM:89683805

Id:36f3099c-c2d8-5ceb-8f4d-262a3126dc7a

Description:nan

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Enasidenib's neighborhood in the knowledge graph.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Enasidenib.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Enasidenib.

Results found

Linked to

	Label	Description
	BRD-K70601687-001-01-3 Substance (Entity type)	A Substance
	DCSTRUCT ID 05251 Collection (Entity type)	DrugPage Collection: (DrugCentralID:05251; PubChem_CID:89683805, FILE=drugcentral_drug_05251.json)
	enasidenib (efeb90c6-304c-4925-a099-c3161cb8de62) Collection (Entity type)	Metadatata for enasidenib
	Enasidenib negatively regulates TNFAIP3 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Enasidenib positively regulates ENPP1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Enasidenib positively regulates TCN1 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Enasidenib negatively regulates RAD23B Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Enasidenib negatively regulates TIPARP Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Enasidenib negatively regulates GADD45A Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS
	Enasidenib negatively regulates SYNE3 Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from LINCS